The proposed volume attempts to understand how forms of bio-innovation might be linked to the problem of poverty and its reduction through an inquiry into a number of empirical cases of present-day bio-innovations in Asia. Conditions and circumstances in countries like Cambodia, China, India, Korea, Nepal, Philippines, and Thailand are quite different and provide a mosaic of varied experiences in bio-innovation that include shrimp farming, GMO cotton, bio gas, organic farming, and vaccines.

Offering important insights into various forms of bio-innovation efforts and their effects on poverty alleviation, this volume is divided into three major themes that organize the main sections of the book—benefits for the poor: actual, direct, and prospective benefits for the poor; absence of positive impacts and institutional constraints; pro-poor drivers and embedding in anti-poverty alleviation.

The central questions addressed here are: Ways and circumstances in which certain forms of bio-innovations affect the poor and enable poverty alleviation.; Critical factors and conditions for improving the positive impact of bio-innovations on poverty alleviation.; Poverty alleviation goals should be the point of departure in rationalizing, identifying and designing appropriate and relevant bio-innovation programs.

Changing Trends of Bio-Innovation in Pharmaceutical Industry: Inclusion and Exclusion of Poor

Changing Trends of Bio-Innovation in Pharmaceutical Industry: Inclusion and Exclusion of Poor

Changing trends of bio-innovation in pharmaceutical industry: Inclusion and exclusion of poor

Focal Bio-Innovation Issues

This chapter is based on a research project to explore the premise that structural inequality is embedded in the global pharmaceutical market, which leads to worsening the poverty of the poorer in less developed and developing countries. As a departure point, the researcher noted the uneven geographical distribution of major pharmaceutical companies viz. the world's 10 biggest pharmaceutical companies are based in Euro-American countries while most developing countries (except for India) lag behind in pharmaceutical production infrastructure.

Under these circumstances, the project intended to examine the following question: Who are the beneficiaries of bio-innovations? How do the poor benefit from scientific ...

  • Loading...
locked icon

Sign in to access this content

Get a 30 day FREE TRIAL

  • Watch videos from a variety of sources bringing classroom topics to life
  • Read modern, diverse business cases
  • Explore hundreds of books and reference titles